<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321854</url>
  </required_header>
  <id_info>
    <org_study_id>248.595</org_study_id>
    <nct_id>NCT00321854</nct_id>
  </id_info>
  <brief_title>Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a double blind, placebo-controlled clinical trial of 15 months duration designed to
      examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in
      patients with new onset Parkinsons disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15</measure>
    <time_frame>Month 15</time_frame>
    <description>The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse). Responders are defined as those patients with a CGI-I of 1 or 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The CGI-S measures the participants severity of illness on an ordinal scale ranging from 1 (normal) to 7 (extremely ill). At Month 15 participants were categorised to 'Improved' (&gt;1 category improvement), 'Unchanged' or 'Worsened' (&gt;1 category worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15</measure>
    <time_frame>Month 15</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15</measure>
    <time_frame>Month 15</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9</measure>
    <time_frame>Month 9</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15</measure>
    <time_frame>Month 15</time_frame>
    <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in the Striatum Uptake at Month 15</measure>
    <time_frame>Baseline and Month 15</time_frame>
    <description>The striatum beta-carbomethoxy-iodophenyl-tropane (beta-CIT) uptake was calculated as mean of the left and right caudate and putamen regions; measured by the Single-Photon Emission Computed Tomography (SPECT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Haematology and Electrolytes</measure>
    <time_frame>Baseline and Month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Enzymes</measure>
    <time_frame>Baseline and Month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Substrates</measure>
    <time_frame>Baseline and Month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Abnormalities in Vital Signs</measure>
    <time_frame>Baseline and Month 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">535</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Early Pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
    <arm_group_label>Early Pramipexole</arm_group_label>
    <arm_group_label>Delayed Pramipexole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation;

          -  Male or female patient with idiopathic Parkinson Disease (PD) confirmed by at least
             three of the following signs: resting tremor, bradykinesia, rigidity, and asymmetry
             (must have bradykinesia);

          -  Parkinsons disease newly diagnosed within the past 2 years;

          -  Patients with idiopathic PD characterized as Stage I-II by the Modified Hoehn and Yahr
             Scale who do not require PD medication and will not likely need PD medication for at
             least 6 months in the opinion of the investigator; Age 30 to 75 years at screening
             (Visit 1);

          -  Women of childbearing potential must have a negative serum
             Beta-HumanChorionGonadotropin (Beta-HCG) pregnancy test at the Screening (Baseline)
             visit unless surgically sterile or post-menopausal (last menstruation 12 months prior
             to signing Informed Consent). Women of childbearing potential must be using a
             medically accepted contraceptive method. Acceptable methods of birth control are
             limited to: Intra-Uterine Device (IUD), oral, implantable, or injectable
             contraceptives, estrogen patch, and double barrier method (spermicide + diaphragm);
             and Patients who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Previous history of allergic response or complications with pramipexole (PPX) or its
             excipients;

          -  Atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine) or
             metabolic disorders (e.g., Wilsons Disease), encephalitis, or degenerative diseases
             (e.g., progressive supranuclear palsy);

          -  The patient is currently on L-dopa, dopamine agonists or other PD medication at
             baseline;

          -  The patient has been on L-dopa, dopamine agonists or other PD medications for greater
             than 14 consecutive days prior to baseline;

          -  If on L-dopa, dopamine agonists or other PD medications prior to baseline, the patient
             stopped treatment less than 30 days prior to baseline;

          -  The patient has clinically significant abnormal laboratory values, and/or medical or
             psychiatric illness other than as seen in Parkinsons disease;

          -  The patient has a clinically significant deviation from normal in the physical
             examination other than as seen in Parkinsons disease;

          -  The patient has any disorder that may interfere with drug absorption, distribution,
             metabolism, or excretion (including gastrointestinal surgery);

          -  History of stereotactic brain surgery;

          -  Surgery within 6 months of randomization, which in the opinion of the investigator,
             would negatively impact the patients participation in the study;

          -  History of active epilepsy (i.e., occurrence of a seizure) within the past year;

          -  Symptomatic orthostatic hypotension prior to randomization;

          -  Malignant melanoma or history of previously treated malignant melanoma;

          -  Patients who have received any of the following drugs (all time periods are calculated
             from randomization): Amantadine;

          -  Electroconvulsive therapy during 180 days preceding the screening visit (Visit 1);

          -  Patients who are currently pregnant or planning pregnancy during the study, or
             lactating;

          -  Participation in other investigational drug studies or use of other investigational
             drugs within the previous 30 days prior to randomization;

          -  History of psychosis;

          -  A diagnosis of dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.595.0122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brimingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scarbourough</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.0121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruck a. d. Mur</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3306A Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3306B Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3306C Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3301A Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3301B Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3303A Cabinet Médical</name>
      <address>
        <city>Evreux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3307A Hôpital Roger Salengro</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3307B Hôpital Roger Salengro</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3302A Hôpital La Timone</name>
      <address>
        <city>Marseille cedex 05</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3302B Hôpital La Timone</name>
      <address>
        <city>Marseille cedex 05</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3305A Hôpital Purpan</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.3305C Hôpital Purpan</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39004 Università degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39009 Ospedale di Bellaria</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39005 Ospedale della Misericordia</name>
      <address>
        <city>Grosseto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39001 Azienda Ospedaliera Istituti Clinici di Perfezionamento</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39010 Ospedale Maggiore Policlinico Mangigalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39011 Ospedale S. Raffaele - IRCCS</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39002 Università Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39012 Azienda Ospedaliera Pisana- Università degli Studi di Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39006 Policlinico Universitario Molinette</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39007 Ospedale Evangelico Valdese</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39013 Ospedale Umberto I</name>
      <address>
        <city>Venezia Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.39003 Ospedale di Viareggio</name>
      <address>
        <city>Viareggio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.81001 Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.81002 Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.34003 Hospital de Alcorcon</name>
      <address>
        <city>Alcorcon (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.34001 Hospital Clinic i Provincial of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.34002 Nuevo Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.34004 Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.34005 Hospital Mutua de Terrassa</name>
      <address>
        <city>Tarrasa (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norrköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newark</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.595.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2006</study_first_submitted>
  <study_first_submitted_qc>May 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <results_first_submitted>December 18, 2009</results_first_submitted>
  <results_first_submitted_qc>December 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2010</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Pramipexole</title>
          <description>Patients initially randomized to pramipexole were up-titrated from 0.375 mg pramipexole daily to 0.75 mg pramipexole daily and then to 1.5 mg pramipexole daily over a 6 week period, and then 1.5 mg pramipexole daily was continued for the remainder of the 15 months of the study.</description>
        </group>
        <group group_id="P2">
          <title>Delayed Pramipexole</title>
          <description>Patients initially randomized to placebo, received placebo for 6-9 months, then up-titrated from 0.375 mg pramipexole daily to 1.5 mg pramipexole daily over a 6 week period. These patients were then continued on 1.5 mg pramipexole daily for the remainder of the 15 months of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Pramipexole</title>
          <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
        </group>
        <group group_id="B2">
          <title>Delayed Pramipexole</title>
          <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="261"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="535"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Treated set (TS)</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="10.1"/>
                    <measurement group_id="B2" value="62.9" spread="9.9"/>
                    <measurement group_id="B3" value="62.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Treated set (TS)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15</title>
        <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The Phase 2 Full Analysis Set (FAS2) was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15</title>
          <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
          <population>The Phase 2 Full Analysis Set (FAS2) was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.7"/>
                    <measurement group_id="O2" value="0.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6503</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15</title>
        <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15</title>
          <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.7"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9568</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9</title>
        <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9</title>
          <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.6"/>
                    <measurement group_id="O2" value="4.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>-3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6</title>
        <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6</title>
          <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.6"/>
                    <measurement group_id="O2" value="2.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>-3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3</title>
        <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3</title>
          <description>The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15</title>
        <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15</title>
          <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.7"/>
                    <measurement group_id="O2" value="0.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8693</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15</title>
        <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15</title>
          <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.7"/>
                    <measurement group_id="O2" value="0.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8155</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9</title>
        <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9</title>
          <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.6"/>
                    <measurement group_id="O2" value="4.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>-3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6</title>
        <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6</title>
          <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.6"/>
                    <measurement group_id="O2" value="2.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3</title>
        <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3</title>
          <description>The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="0.5"/>
                    <measurement group_id="O2" value="0.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15</title>
        <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15</title>
          <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7999</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15</title>
        <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15</title>
          <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7395</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9</title>
        <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9</title>
          <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.5"/>
                    <measurement group_id="O2" value="2.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6</title>
        <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6</title>
          <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.4"/>
                    <measurement group_id="O2" value="1.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3</title>
        <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3</title>
          <description>The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.4"/>
                    <measurement group_id="O2" value="-0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15</title>
        <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15</title>
          <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9256</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15</title>
        <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15</title>
          <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9792</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9</title>
        <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9</title>
          <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6</title>
        <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6</title>
          <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3</title>
        <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3</title>
          <description>The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15</title>
        <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15</title>
          <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0376</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15</title>
        <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15</title>
          <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.1"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1607</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9</title>
        <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9</title>
          <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6</title>
        <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6</title>
          <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3</title>
        <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3</title>
          <description>The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.1"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4381</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15</title>
        <description>The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse). Responders are defined as those patients with a CGI-I of 1 or 2.</description>
        <time_frame>Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 27 patients from the FAS2 were excluded due to insufficient CGI-I data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15</title>
          <description>The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse). Responders are defined as those patients with a CGI-I of 1 or 2.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 27 patients from the FAS2 were excluded due to insufficient CGI-I data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5116</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.796</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.403</ci_lower_limit>
            <ci_upper_limit>1.573</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15</title>
        <description>The CGI-S measures the participants severity of illness on an ordinal scale ranging from 1 (normal) to 7 (extremely ill). At Month 15 participants were categorised to 'Improved' (&gt;1 category improvement), 'Unchanged' or 'Worsened' (&gt;1 category worsening).</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 4 patients from the FAS2 were excluded due to insufficient CGI-I data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15</title>
          <description>The CGI-S measures the participants severity of illness on an ordinal scale ranging from 1 (normal) to 7 (extremely ill). At Month 15 participants were categorised to 'Improved' (&gt;1 category improvement), 'Unchanged' or 'Worsened' (&gt;1 category worsening).</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 4 patients from the FAS2 were excluded due to insufficient CGI-I data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Essentially unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ordinal responses (3 levels) were analysed using the proportional odds model extension of logistic regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7913</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.153</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.403</ci_lower_limit>
            <ci_upper_limit>3.299</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15</title>
        <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient BDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15</title>
          <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient BDI data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0.3"/>
                    <measurement group_id="O2" value="-0.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1702</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9</title>
        <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9</title>
          <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6</title>
        <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6</title>
          <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3</title>
        <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 2 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3</title>
          <description>The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 2 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0.3"/>
                    <measurement group_id="O2" value="-0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0422</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15</title>
        <description>The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15</title>
          <description>The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="-0.4" lower_limit="-3.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="0.3" spread="0.3" lower_limit="-3.6" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2149</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.573</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.823</ci_lower_limit>
            <ci_upper_limit>0.677</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9</title>
        <description>The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9</title>
          <description>The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="-0.5" lower_limit="-3.6" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.4" spread="1.4" lower_limit="-2.2" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.125</ci_lower_limit>
            <ci_upper_limit>-0.938</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15</title>
        <description>The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15</title>
          <description>The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 1 patient from the FAS2 was excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="-0.026" upper_limit="0.092"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="-0.079" upper_limit="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2605</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9</title>
        <description>The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9</title>
          <description>The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 3 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="-0.026" upper_limit="0.092"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="-0.140" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15</title>
        <description>The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 2 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15</title>
          <description>The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 2 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="-8.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="-10.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0489</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9</title>
        <description>The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 5 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9</title>
          <description>The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 5 patients from the FAS2 were excluded due to insufficient efficacy data.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="-5.5" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-0.5" spread="-0.5" lower_limit="-10.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0282</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
        <time_frame>Month 1</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 132 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 132 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
        <time_frame>Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
        <time_frame>Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
        <time_frame>Month 12</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 140 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 140 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
        <time_frame>Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 134 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 134 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risk of gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
        <time_frame>Month 1</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 132 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 132 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
        <time_frame>Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
        <time_frame>Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
        <time_frame>Month 12</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 140 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 140 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
        <time_frame>Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 134 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 134 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive sexual behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
        <time_frame>Month 1</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 132 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 132 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
        <time_frame>Month 6</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
        <time_frame>Month 9</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 131 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
        <time_frame>Month 12</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 140 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 140 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15</title>
        <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
        <time_frame>Month 15</time_frame>
        <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 134 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15</title>
          <description>The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.</description>
          <population>The FAS2 was made up of all treated participants with a baseline and on-treatment blinded rater assessment of the UPDRS during Phase 2 of the trial. 134 patients from the FAS2 were excluded due to insufficient MMIDI data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in the Striatum Uptake at Month 15</title>
        <description>The striatum beta-carbomethoxy-iodophenyl-tropane (beta-CIT) uptake was calculated as mean of the left and right caudate and putamen regions; measured by the Single-Photon Emission Computed Tomography (SPECT).</description>
        <time_frame>Baseline and Month 15</time_frame>
        <population>The substudy set was made up of all randomised patients with a baseline and end of treatment assessment of striatal uptake.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in the Striatum Uptake at Month 15</title>
          <description>The striatum beta-carbomethoxy-iodophenyl-tropane (beta-CIT) uptake was calculated as mean of the left and right caudate and putamen regions; measured by the Single-Photon Emission Computed Tomography (SPECT).</description>
          <population>The substudy set was made up of all randomised patients with a baseline and end of treatment assessment of striatal uptake.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" spread="2.1"/>
                    <measurement group_id="O2" value="-14.6" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8397</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Haematology and Electrolytes</title>
        <time_frame>Baseline and Month 15</time_frame>
        <population>Treated set: Haematocrit and mean corpuscular volume (MCV-N) was 211 for Early PPX and 209 for Delayed PPX, Haemoglobin-N was 213 for Early PPX and 212 for Delayed PPX, Sodium-N was 211 for Early PPX and 209 for Delayed PPX, Calcium and Chloride-N was 214 for Early PPX and 209 for Delayed PPX, Phosphate-N was 201 for Early and Delayed PPX</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>Patients initially randomized to pramipexole were up-titrated from 0.375 mg pramipexole daily to 0.75 mg pramipexole daily and then to 1.5 mg pramipexole daily over a 6 week period, and then 1.5 mg pramipexole daily was continued for the remainder of the 15 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Patients initially randomized to placebo, received placebo for 6-9 months, then up-titrated from 0.375 mg pramipexole daily to 1.5 mg pramipexole daily over a 6 week period. These patients were then continued on 1.5 mg pramipexole daily for the remainder of the 15 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Haematology and Electrolytes</title>
          <population>Treated set: Haematocrit and mean corpuscular volume (MCV-N) was 211 for Early PPX and 209 for Delayed PPX, Haemoglobin-N was 213 for Early PPX and 212 for Delayed PPX, Sodium-N was 211 for Early PPX and 209 for Delayed PPX, Calcium and Chloride-N was 214 for Early PPX and 209 for Delayed PPX, Phosphate-N was 201 for Early and Delayed PPX</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematocrit - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Enzymes</title>
        <time_frame>Baseline and Month 15</time_frame>
        <population>Gamma Glutamyltranspeptidase (GGT-N) was 214 for Early PPX and 208 for Delayed PPX, Amylase-N was 214 for Early PPX and 209 for Delayed PPX</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>Patients initially randomized to pramipexole were up-titrated from 0.375 mg pramipexole daily to 0.75 mg pramipexole daily and then to 1.5 mg pramipexole daily over a 6 week period, and then 1.5 mg pramipexole daily was continued for the remainder of the 15 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Patients initially randomized to placebo, received placebo for 6-9 months, then up-titrated from 0.375 mg pramipexole daily to 1.5 mg pramipexole daily over a 6 week period. These patients were then continued on 1.5 mg pramipexole daily for the remainder of the 15 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Enzymes</title>
          <population>Gamma Glutamyltranspeptidase (GGT-N) was 214 for Early PPX and 208 for Delayed PPX, Amylase-N was 214 for Early PPX and 209 for Delayed PPX</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GGT - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Substrates</title>
        <time_frame>Baseline and Month 15</time_frame>
        <population>Glucose-N was 28 for Early PPX and 46 for Delayed PPX, Cholesterol and Triglyceride-N was 213 for Early PPX and 208 for Delayed PPX, Blood Urea Nitrogen-N was 214 for Early PPX and 209 for Delayed PPX, Creatinine-N was 200 for Early PPX and 202 for Delayed PPX, Uric Acid-N was 212 for Early PPX and 209 for Delayed PPX.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>Patients initially randomized to pramipexole were up-titrated from 0.375 mg pramipexole daily to 0.75 mg pramipexole daily and then to 1.5 mg pramipexole daily over a 6 week period, and then 1.5 mg pramipexole daily was continued for the remainder of the 15 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Patients initially randomized to placebo, received placebo for 6-9 months, then up-titrated from 0.375 mg pramipexole daily to 1.5 mg pramipexole daily over a 6 week period. These patients were then continued on 1.5 mg pramipexole daily for the remainder of the 15 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Abnormalities in Clinical Laboratory Measurements - Substrates</title>
          <population>Glucose-N was 28 for Early PPX and 46 for Delayed PPX, Cholesterol and Triglyceride-N was 213 for Early PPX and 208 for Delayed PPX, Blood Urea Nitrogen-N was 214 for Early PPX and 209 for Delayed PPX, Creatinine-N was 200 for Early PPX and 202 for Delayed PPX, Uric Acid-N was 212 for Early PPX and 209 for Delayed PPX.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose - decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid - increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Abnormalities in Vital Signs</title>
        <time_frame>Baseline and Month 15</time_frame>
        <population>Phase 1 Treated set for sinus bradycardia with N of 261 for Early PPX and 274 for Delayed PPX. Phase 2 Treated set for hypotension with N of 221 for Early PPX and 214 for Delayed PPX.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Pramipexole</title>
            <description>Patients initially randomized to pramipexole were up-titrated from 0.375 mg pramipexole daily to 0.75 mg pramipexole daily and then to 1.5 mg pramipexole daily over a 6 week period, and then 1.5 mg pramipexole daily was continued for the remainder of the 15 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Pramipexole</title>
            <description>Patients initially randomized to placebo, received placebo for 6-9 months, then up-titrated from 0.375 mg pramipexole daily to 1.5 mg pramipexole daily over a 6 week period. These patients were then continued on 1.5 mg pramipexole daily for the remainder of the 15 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Abnormalities in Vital Signs</title>
          <population>Phase 1 Treated set for sinus bradycardia with N of 261 for Early PPX and 274 for Delayed PPX. Phase 2 Treated set for hypotension with N of 221 for Early PPX and 214 for Delayed PPX.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sinus bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Onset date after the date of first dose up to 48 hours after last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early Pramipexole</title>
          <description>1.5 milligrams/day pramipexole (for up to 15 months)</description>
        </group>
        <group group_id="E2">
          <title>Delayed Pramipexole</title>
          <description>Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Small intestine obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteristis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Radial nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Large cell carcinoma of the respiratory tract stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pakinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pakinsonism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occulsive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

